CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $4.79B, above the global median of $1.18B
- FinancialsAltman Z-Score 3.01: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
4.79BUSDvs all stocks (USD)
Trailing P/E
50.87xvs Medical Devices peers
Revenue (TTM)
1.35BUSDvs all stocks (USD)
Profit Margin
7.12%vs Medical Devices peers
Beta
0.5430xvs all stocks
52-Week Change
118.83%vs all stocks
Market Capitalization
4.79BUSDvs all stocks (USD)
Enterprise Value
5.74BUSDvs all stocks (USD)
Trailing P/E
50.87xvs Medical Devices peers
Forward P/E
18.23xvs Medical Devices peers
PEG Ratio
17.66xvs Medical Devices peers
Price to Sales (TTM)
3.54xvs Medical Devices peers
Price to Book (MRQ)
5.72xvs Medical Devices peers
Enterprise to Revenue
4.25xvs Medical Devices peers
Enterprise to EBITDA
16.00xvs Medical Devices peers
Gross Margin
59.76%vs Medical Devices peers
Profit Margin
7.12%vs Medical Devices peers
Operating Margin
17.93%vs Medical Devices peers
Return on Assets (TTM)
6.60%vs Medical Devices peers
Return on Equity (TTM)
11.20%vs Medical Devices peers
Revenue (TTM)
1.35BUSDvs all stocks (USD)
Revenue per Share (TTM)
29.08USDUpdated Sep 27, 2026Quarterly Revenue Growth
5.60%vs Medical Devices peers
Gross Profit (TTM)
802.16MUSDvs all stocks (USD)
EBITDA (TTM)
355.06MUSDvs all stocks (USD)
Net Income (TTM)
96.29MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-3.00%vs Medical Devices peers
Operating Cash Flow (TTM)
328.15MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
312.84MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Revenue
1.33BUSDFY2026 · Mar 31, 2026Cost of Goods Sold
546.44MUSDFY2026 · Mar 31, 2026Gross Profit
787.59MUSDFY2026 · Mar 31, 2026Operating Income
241.40MUSDvs all stocks (USD)
Pre-tax Income
128.03MUSDFY2026 · Mar 31, 2026Income Tax Expense
30.72MUSDFY2026 · Mar 31, 2026Net Income
97.31MUSDFY2026 · Mar 31, 2026EBIT
156.73MUSDFY2026 · Mar 31, 2026EBITDA (Income Statement)
353.12MUSDFY2026 · Mar 31, 2026Research & Development
59.77MUSDFY2026 · Mar 31, 2026Selling, General & Administrative
442.42MUSDFY2026 · Mar 31, 2026Non-operating Interest Expense
28.70MUSDFY2026 · Mar 31, 2026EPS (Basic)
2.06USDFY2026 · Mar 31, 2026EPS (Diluted)
2.05USDFY2026 · Mar 31, 2026Basic Shares Outstanding
47.18MSharesFY2026 · Mar 31, 2026Diluted Shares Outstanding
47.18MSharesFY2026 · Mar 31, 2026Net Income from Continuing Operations
97.31MUSDFY2026 · Mar 31, 2026Operating Cash Flow
254.25MUSDFY2026 · Mar 31, 2026Free Cash Flow
252.88MUSDFY2026 · Mar 31, 2026Cash & Cash Equivalents (End of Period)
245.44MUSDFY2026 · Mar 31, 2026Starting Profit (CF Statement)
97.31MUSDFY2026 · Mar 31, 2026Depreciation & Amortization
111.72MUSDFY2026 · Mar 31, 2026Deferred Taxes (CF)
-714.00KUSDFY2026 · Mar 31, 2026Stock-based Compensation
33.83MUSDFY2026 · Mar 31, 2026Other Non-cash Items
3.94MUSDFY2026 · Mar 31, 2026Change in Accounts Receivable (CF)
-14.88MUSDFY2026 · Mar 31, 2026Change in Other Assets/Liabilities
23.06MUSDFY2026 · Mar 31, 2026Capital Expenditures
1.38MUSDFY2026 · Mar 31, 2026Net Acquisitions
-60.18MUSDFY2026 · Mar 31, 2026Other Investing Activity
-51.89MUSDFY2026 · Mar 31, 2026Net Investing Cash Flow
-110.70MUSDFY2026 · Mar 31, 2026Long-term Debt Issuance
300.00MUSDFY2026 · Mar 31, 2026Long-term Debt Payments
-306.25MUSDFY2026 · Mar 31, 2026Common Stock Repurchase
-175.00MUSDFY2026 · Mar 31, 2026Other Financing Charges
-102.00KUSDFY2026 · Mar 31, 2026Net Financing Cash Flow
-181.35MUSDFY2026 · Mar 31, 2026Shares Outstanding
45.47MSharesUpdated Sep 27, 2026Float Shares
44.89MSharesUpdated Sep 27, 2026Shares Short
3.42MSharesUpdated Sep 27, 2026Short Ratio
4.71daysvs all stocks
Short % of Shares Outstanding
8.81%vs all stocks
% Held by Insiders
1.26%vs all stocks
% Held by Institutions
112.55%vs all stocks
Total Cash (MRQ)
224.52MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
4.93USDUpdated Sep 27, 2026Total Debt (MRQ)
1.17BUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
1.40xvs Medical Devices peers
Current Ratio (MRQ)
3.08xvs Medical Devices peers
Book Value per Share (MRQ)
18.41USDUpdated Sep 27, 2026Total Assets
2.40BUSDvs all stocks (USD)
Total Current Assets
834.88MUSDFY2026 · Mar 31, 2026Total Liabilities
1.60BUSDFY2026 · Mar 31, 2026Total Non-current Assets
1.56BUSDFY2026 · Mar 31, 2026Total Non-current Liabilities
1.32BUSDFY2026 · Mar 31, 2026Total Current Liabilities
282.60MUSDFY2026 · Mar 31, 2026Cash & Cash Equivalents
245.44MUSDFY2026 · Mar 31, 2026Accounts Receivable
216.85MUSDFY2026 · Mar 31, 2026Inventory
306.37MUSDFY2026 · Mar 31, 2026Accounts Payable
51.06MUSDFY2026 · Mar 31, 2026Short-term Debt
5.01MUSDFY2026 · Mar 31, 2026Deferred Revenue
42.31MUSDFY2026 · Mar 31, 2026Other Current Liabilities
116.03MUSDFY2026 · Mar 31, 2026Long-term Debt
1.22BUSDFY2026 · Mar 31, 2026Other Non-current Liabilities
59.39MUSDFY2026 · Mar 31, 2026Common Stock (Book)
453.00KUSDFY2026 · Mar 31, 2026Retained Earnings
279.34MUSDFY2026 · Mar 31, 2026Total Shareholders' Equity
796.32MUSDvs all stocks (USD)
52-Week Low
47.56USDUpdated Sep 27, 202652-Week High
110.45USDUpdated Sep 27, 202652-Week Change
118.83%vs all stocks
Beta
0.5430xvs all stocks
50-Day MA
95.62USDUpdated Sep 27, 2026200-Day MA
74.38USDUpdated Sep 27, 2026Avg 10-Day Volume
615.80KSharesUpdated Sep 27, 2026Avg 30-Day Volume
688.10KSharesUpdated Sep 27, 2026Diluted EPS (TTM)
2.07USDUpdated Sep 27, 2026Other Income / Expense
-84.67MUSDFY2026 · Mar 31, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.60Profit Margin: 0.07
Financial Health
Altman Z-Score 3.01: safe zoneNotable
Altman Z-Score: 3.01
High earnings qualityNotable
Earnings Quality Score: 1.10
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $4.79B, above the global median of $1.18BNotable
Market cap (USD): 4,790,839,470Global Median: 1,180,223,658.953
Revenue is $1.35B, above the global median of $548.88MNotable
Revenue (USD): 1,352,013,056Global Median: 548,883,780.48
Levered free cash flow is $312.84M, above the global median of $18.73MNotable
Levered free cash flow (USD): 312,840,000Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
Shanghai Henlius Biotech, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Tong Ren Tang Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Shanghai RAAS Blood Products Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Definium Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Veradermics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Suzhou Zelgen Biopharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Dianthus Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Anthem Biosciences Limited
Tier 1ProductionApproval-Gated PipelineFlowSenseMaking
Hanmi Pharm Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Shanghai Action Education Technology Co., Ltd.
1 interpretationFCF Ratios Elevated
Xuzhou Handler Special Vehicle Co., Ltd.
1 interpretationFCF Ratios Elevated
Comfort Systems USA, Inc.
1 interpretationFCF Ratios Elevated